215 related articles for article (PubMed ID: 32909840)
1. Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives.
Overvad TF; Larsen TB; Søgaard M; Albertsen IE; Ording AG; Noble S; Højen AA; Nielsen PB
Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):791-800. PubMed ID: 32909840
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Howard LS
Expert Rev Respir Med; 2018 May; 12(5):387-402. PubMed ID: 29542359
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
6. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
7. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Bacchus F; Schulman S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):513-9. PubMed ID: 25717178
[TBL] [Abstract][Full Text] [Related]
9. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
10. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
11. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
13. Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Yeh CH; Gross PL; Weitz JI
Blood; 2014 Aug; 124(7):1020-8. PubMed ID: 24923298
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
15. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
Pritchard ER; Murillo JR; Putney D; Hobaugh EC
J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
[TBL] [Abstract][Full Text] [Related]
16. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
Ravikumar R; Lim CS; Davies AH
Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Dobesh PP; Fanikos J
Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
[TBL] [Abstract][Full Text] [Related]
19. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Bass AR
Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
[TBL] [Abstract][Full Text] [Related]
20. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Verso M; Agnelli G; Prandoni P
Intern Emerg Med; 2015 Sep; 10(6):651-6. PubMed ID: 25840679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]